Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

BrainsWay Ltd.

BWAYNASDAQ
Healthcare
Medical - Devices
$23.90
$0.00(0.00%)
U.S. Market is Open • 15:53

BrainsWay Ltd. Fundamental Analysis

BrainsWay Ltd. (BWAY) shows moderate financial fundamentals with a PE ratio of 73.24, profit margin of 12.73%, and ROE of 9.46%. The company generates $0.1B in annual revenue with strong year-over-year growth of 29.04%.

Key Strengths

Cash Position15.37%
PEG Ratio0.73
Current Ratio3.19

Areas of Concern

ROE9.46%
Operating Margin5.78%
We analyze BWAY's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 69.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
69.5/100

We analyze BWAY's fundamental strength across five key dimensions:

Efficiency Score

Weak

BWAY struggles to generate sufficient returns from assets.

ROA > 10%
5.53%

Valuation Score

Moderate

BWAY shows balanced valuation metrics.

PE < 25
73.24
PEG Ratio < 2
0.73

Growth Score

Moderate

BWAY shows steady but slowing expansion.

Revenue Growth > 5%
29.04%
EPS Growth > 10%
1.66%

Financial Health Score

Excellent

BWAY maintains a strong and stable balance sheet.

Debt/Equity < 1
0.10
Current Ratio > 1
3.19

Profitability Score

Weak

BWAY struggles to sustain strong margins.

ROE > 15%
9.46%
Net Margin ≥ 15%
12.73%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BWAY Expensive or Cheap?

P/E Ratio

BWAY trades at 73.24 times earnings. This suggests a premium valuation.

73.24

PEG Ratio

When adjusting for growth, BWAY's PEG of 0.73 indicates potential undervaluation.

0.73

Price to Book

The market values BrainsWay Ltd. at 6.53 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.53

EV/EBITDA

Enterprise value stands at 60.37 times EBITDA. This signals the market has high growth expectations.

60.37

How Well Does BWAY Make Money?

Net Profit Margin

For every $100 in sales, BrainsWay Ltd. keeps $12.73 as profit after all expenses.

12.73%

Operating Margin

Core operations generate 5.78 in profit for every $100 in revenue, before interest and taxes.

5.78%

ROE

Management delivers $9.46 in profit for every $100 of shareholder equity.

9.46%

ROA

BrainsWay Ltd. generates $5.53 in profit for every $100 in assets, demonstrating efficient asset deployment.

5.53%

Following the Money - Real Cash Generation

Operating Cash Flow

BrainsWay Ltd. generates strong operating cash flow of $23.68M, reflecting robust business health.

$23.68M

Free Cash Flow

BrainsWay Ltd. generates strong free cash flow of $19.50M, providing ample flexibility for dividends, buybacks, or growth.

$19.50M

FCF Per Share

Each share generates $0.97 in free cash annually.

$0.97

FCF Yield

BWAY converts 3.81% of its market value into free cash.

3.81%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

73.24

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.73

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.53

vs 25 benchmark

P/S Ratio

Price to sales ratio

9.91

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.19

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.09

vs 25 benchmark

ROA

Return on assets percentage

0.06

vs 25 benchmark

ROCE

Return on capital employed

0.03

vs 25 benchmark

How BWAY Stacks Against Its Sector Peers

MetricBWAY ValueSector AveragePerformance
P/E Ratio73.2429.43 Worse (Expensive)
ROE9.46%800.00% Weak
Net Margin12.73%-20145.00% (disorted) Strong
Debt/Equity0.100.30 Strong (Low Leverage)
Current Ratio3.194.64 Strong Liquidity
ROA5.53%-17936.00% (disorted) Weak

BWAY outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BrainsWay Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

4.72%

Industry Style: Defensive, Growth, Innovation

Growing

EPS CAGR

116.68%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

183.84%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ